BioScience Ventures Group AG is a venture capital firm based in Munich, Germany, that specializes in seed and early-stage investments in the life sciences sector. Focusing primarily on pharmaceuticals, biotechnology, medical technology, and medical devices, the firm targets companies located in Germany, Austria, and Switzerland. BioScience Ventures Group typically invests between €0.2 million and €0.5 million in each investment round and prefers to take a board seat in its portfolio companies. Established in 2001, the firm is composed of a team of experienced business angels with backgrounds in medicine and pharmacology, which equips them to support drug development and the design of preclinical and clinical studies, particularly in the area of biologics, such as antibodies and proteins.
Nano4Imaging GmbH, founded in 2011 and based in Aachen, Germany, specializes in the development and production of contrast agents and devices designed for in-vivo imaging of medical implants and minimal invasive devices, such as catheters and guidewires. The company offers products like MRWire EmeryGlide, a guide wire compatible with magnetic resonance imaging (MRI), and the MagnaFy series, which includes coatings that enhance visibility under MRI, computed tomography (CT), and X-ray imaging. These innovations facilitate medical interventions and therapies, particularly in the treatment of cardiovascular diseases and during radiotherapy, allowing for precise monitoring of medical devices during procedures. By leveraging nanotechnology, Nano4Imaging aims to enhance diagnostic imaging capabilities for healthcare professionals.
MagnaMedics
Series B in 2011
MagnaMedics specializes in the engineering and production of magnetic nano- and microparticles designed for use in medical devices, drug delivery systems, and diagnostic kits. These particles facilitate the determination of biomarkers in body fluids, with a particular focus on proteomics. The company emphasizes high-quantity isolation of proteins, catering to researchers engaged in high-throughput screening of biomarkers. By providing innovative solutions, MagnaMedics enables manufacturers to conduct in-vitro diagnostics more efficiently and effectively.
APEPTICO Forschung und Entwicklung
Series A in 2010
Apeptico Forschung und Entwicklung GmbH is a biotechnology company based in Vienna, Austria, established in 2008. The company specializes in the development and marketing of peptide-based therapeutic drugs aimed at treating chronic and life-threatening diseases. Its primary product portfolio includes PEPBASE, which features various peptide-based medicinal solutions designed for both therapeutic and prophylactic applications. Through its innovative approach, Apeptico focuses on addressing significant medical needs in the realm of severe health conditions.
Diaferon
Seed Round in 2007
Diaferon is a biotechnology company developing a drug delivery system to control the release and distribution of therapeutic particles.
ugichem
Series B in 2007
ugichem is an innovative biotech company based on unique chemistry and focused on the development of novel antisense drugs. Their mission is to turn antisense into therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.